Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Equity: 2011-2025

Historic Return on Equity for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to 0.50%.

  • Adma Biologics' Return on Equity rose 18.00% to 0.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.50%, marking a year-over-year increase of 18.00%. This contributed to the annual value of 0.82% for FY2024, which is 101.00% up from last year.
  • Latest data reveals that Adma Biologics reported Return on Equity of 0.50% as of Q3 2025, which was down 6.73% from 0.54% recorded in Q2 2025.
  • Adma Biologics' Return on Equity's 5-year high stood at 0.68% during Q4 2024, with a 5-year trough of -0.75% in Q1 2021.
  • Over the past 3 years, Adma Biologics' median Return on Equity value was 0.20% (recorded in 2024), while the average stood at 0.17%.
  • Data for Adma Biologics' Return on Equity shows a peak YoY surged of 88bps (in 2024) over the last 5 years.
  • Adma Biologics' Return on Equity (Quarterly) stood at -0.59% in 2021, then climbed by 12bps to -0.46% in 2022, then grew by 27bps to -0.20% in 2023, then soared by 88bps to 0.68% in 2024, then increased by 18bps to 0.50% in 2025.
  • Its Return on Equity was 0.50% in Q3 2025, compared to 0.54% in Q2 2025 and 0.57% in Q1 2025.